Low Testosterone Lawsuit Update On Recent Case Management Conference

Low Testosterone Lawsuit News On Case Management Conference

In this news release, Laurence Banville discusses the recent case management conference dealing with low testosterone lawsuits. Click to read more.
Banville Law reports on the monthly Case Management Conference which was held recently, for Multidistrict Litigation (MDL) 2545, regarding Testosterone Replacement drug therapies, and the liability of those products.

This litigation, which is currently pending, will consider common allegations that the low T therapies cause serious health risks, ranging from blood clots, strokes, heart attacks, and even death.
Doctor discussing low testosterone therapyMany victims suggest that the manufacturers of these products either knew or should have been aware of their dangerous risks, and that they found the manufacturer’s advertising to be misleading, according to documentation linked to the lawsuits.

A Brief History of the Litigation

All lawsuits were consolidated into a MDL in March of 2014, and now consists of almost 2,500 plaintiffs, who have filed lawsuits against various pharmaceutical corporations. The plaintiffs allege that either they, a family member, or a loved one have taken testosterone drugs and have since suffered a number of health complications.

The judge presiding over the MDL, Honorable Judge Matthew F. Kennelly of the United States District Court for the Northern District of Illinois, has issued an order for both plaintiffs and defendants to choose 16 bellwether cases each, however defendant AbbVie has vigorously opposed this, which occupied most of the discussion on the status conference. The initial bellwether trials will shed light on how a jury will perceive specific fact patterns of side effects and injuries allegedly caused by the Low T treatment AndroGel. Other drugs are expected to follow suit mid-year of 2017.

Allegations Against Low T Therapy Manufacturers

Many individuals involved claim that the pharmaceutical companies failed to fulfill their responsibility to properly warn consumers considering use of their testosterone products. Additionally, the allegations say that the pharmaceutical company’s aggressive advertising tactics encouraged even those with undiagnosed symptoms associated with general aging to diagnose themselves with a fabricated condition termed “Low-T” in advertisements. In doing so, the plaintiffs claim, they reached a broad group of men who put themselves at risk by using the drugs without clearly knowing that their symptoms would improve from them.

As men age, their testosterone levels naturally lower, causing symptoms that are considered a normal process of aging. If testosterone levels decrease more dramatically, these symptoms can be more noticeable and difficult to deal with. Symptoms include, decreased sexual drive, increased weight, fatigue, and irritability, and loss of muscle and bone mass, among other things.

Laurence Banville, Esq. of Banville Law is working to assist individuals who may be dealing with health issues after taking low testosterone drugs. “The unfortunate consequence here is that many men have died and several others have long term injuries from heart attacks and strokes after taking low testosterone supplements,” said Banville.

If you would like more information on this issue or your rights to a testosterone lawsuit, please visit LowTestosteroneCase.com or call Laurence Banville, Esq. at 917-809-6595 today.

2016-10-25T16:45:17+00:00

About the Author:

Laurence P. Banville, Esq. is the managing partner of Banville Law. He is a regular contributor on several topics including products liability, nursing home abuse and personal injury.

Got a question for Laurence? Call him directly on: 917-633-4808

Leave A Comment